(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.83%) $83.15
(-1.16%) $1.619
(-0.41%) $2 337.50
(1.00%) $27.53
(0.68%) $928.40
(-0.16%) $0.933
(-0.12%) $11.01
(-0.22%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices...
Stats | |
---|---|
आज की मात्रा | 823.00 |
औसत मात्रा | 592.00 |
बाजार मूल्य | 174.42B |
EPS | €0 ( 2024-04-17 ) |
अगली कमाई की तारीख | ( €0 ) 2024-07-17 |
Last Dividend | €0.510 ( 2023-07-13 ) |
Next Dividend | €0 ( N/A ) |
P/E | 33.51 |
ATR14 | €0 (0.00%) |
Abbott Laboratories सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Abbott Laboratories वित्तीय
Annual | 2023 |
राजस्व: | €40.11B |
सकल लाभ: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2023 |
राजस्व: | €40.11B |
सकल लाभ: | €22.13B (55.18 %) |
EPS: | €3.28 |
FY | 2022 |
राजस्व: | €43.65B |
सकल लाभ: | €24.51B (56.15 %) |
EPS: | €3.99 |
FY | 2021 |
राजस्व: | €43.08B |
सकल लाभ: | €24.54B (56.97 %) |
EPS: | €4.00 |
Financial Reports:
No articles found.
Abbott Laboratories Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.470 (N/A) |
€0.470 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0.510 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.510 | 2023-07-13 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | €22.13 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.9 | -- |
Div. Sustainability Score | 4.40 | |
Div.Growth Potential Score | 7.33 | |
Div. Directional Score | 5.87 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
HBH.DE | Ex Dividend Junior | 2023-07-10 | Annually | 0 | 0.00% | |
RNL.DE | Ex Dividend Junior | 2023-05-17 | Sporadic | 0 | 0.00% | |
BYW6.DE | Ex Dividend Junior | 2023-06-07 | Annually | 0 | 0.00% | |
KBX.DE | Ex Dividend Knight | 2023-05-08 | Annually | 0 | 0.00% | |
THYG.F | Ex Dividend Junior | 2023-08-21 | Semi-Annually | 0 | 0.00% | |
DGR.DE | Ex Dividend Junior | 2023-06-28 | Annually | 0 | 0.00% | |
MRK.DE | Ex Dividend Knight | 2023-05-02 | Annually | 0 | 0.00% | |
5Y7.F | Ex Dividend Knight | 2023-08-08 | Semi-Annually | 0 | 0.00% | |
W8A.DE | Ex Dividend Junior | 2023-08-18 | Quarterly | 0 | 0.00% | |
FC9.DE | Ex Dividend Junior | 2023-06-14 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.140 | 1.500 | 7.21 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.148 | 1.500 | 9.47 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.474 | -1.000 | 5.26 | -5.26 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 22.04 | 1.000 | 2.95 | 2.95 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 8.77 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.552 | 1.000 | 4.13 | 4.13 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.84 | 8.84 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.40 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 33.43 | 1.000 | 6.72 | 0 | [1 - 100] |
returnOnEquityTTM | 0.148 | 2.50 | 9.66 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.45 | 2.00 | 9.18 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.971 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.50 | 2.00 | 8.83 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.474 | 1.500 | 5.26 | -5.26 | [0 - 1] |
pegRatioTTM | 6.47 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.152 | 1.000 | 8.71 | 0 | [0.1 - 0.5] |
Total Score | 7.33 |
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं